Abstract
An immunocompromised patient with an invasive soft tissue infection due to Scedosporium apiospermum was successfully treated with voriconazole and surgical debridement. After transition from intravenous to oral therapy, successive adjustments of the oral dose were required to achieve complete resolution. For soft tissue infections due to molds characterized by thin, septate hyphae branching at acute angles, voriconazole should be considered a first-line antifungal agent. The potential usefulness of plasma voriconazole levels for guiding optimal therapy should be investigated.
MeSH terms
-
Administration, Oral
-
Antifungal Agents / administration & dosage*
-
Antifungal Agents / therapeutic use
-
Arm / pathology
-
Female
-
Hand / pathology
-
Humans
-
Injections, Intravenous
-
Microbial Sensitivity Tests
-
Middle Aged
-
Mycetoma / drug therapy*
-
Mycetoma / microbiology
-
Mycetoma / pathology
-
Mycetoma / surgery
-
Pyrimidines / administration & dosage*
-
Pyrimidines / therapeutic use
-
Scedosporium / drug effects*
-
Soft Tissue Infections / drug therapy*
-
Soft Tissue Infections / pathology
-
Soft Tissue Infections / surgery
-
Treatment Outcome
-
Triazoles / administration & dosage*
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
Voriconazole